Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CLARITIN D.
AZELASTINE HYDROCHLORIDE ALLERGY vs CLARITIN-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine with mast cell stabilizing properties; selectively antagonizes histamine H1 receptors, reducing nasal pruritus, sneezing, rhinorrhea, and ocular symptoms.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
One spray (137 mcg) per nostril twice daily (total 548 mcg/day). Intranasal route.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
The terminal elimination half-life is approximately 22 hours (range 16-26 hours) at steady state, supporting twice-daily dosing. The half-life may be prolonged in elderly patients or those with hepatic impairment.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Azelastine is primarily eliminated via renal excretion (approximately 75% as metabolites, <10% unchanged) and fecal excretion (approximately 25%) after oral administration. Biliary excretion is minimal.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination